Nakahara T, Moriuchi H, Yunoki M, Sakamato K, Ishii K
Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, 5-9-1 Shirokane, Minato-ku, Tokyo, Japan.
Eur J Pharmacol. 2000 Feb 11;389(1):103-6. doi: 10.1016/s0014-2999(99)00891-2.
We examined how (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide (Y-27632), an inhibitor of Rho-associated coiled coil-forming protein kinase (ROCK I) and Rho kinase (ROCK II), affects the relaxant responses to beta(2)-adrenoceptor agonists in bovine tracheal smooth muscle preparations precontracted with methacholine. Y-27632 (0.3-30 microM) caused a concentration-dependent attenuation of precontraction with methacholine (0.3-3 microM). Pretreatment with Y-27632 (1 microM) significantly (P<0.05) augmented salbutamol (0.3-100 nM) and terbutaline (0.3 nM-1 microM)-induced relaxations. These results suggest that the ROCK inhibitor could become a new type bronchodilator and its combination with beta(2)-adrenoceptor agonists may become a novel strategy for the long-term treatment of asthma.
我们研究了Rho相关卷曲螺旋形成蛋白激酶(ROCK I)和Rho激酶(ROCK II)的抑制剂(+)-(R)-反式-4-(1-氨基乙基)-N-(4-吡啶基)环己烷甲酰胺(Y-27632)如何影响在经乙酰甲胆碱预收缩的牛气管平滑肌制剂中对β2-肾上腺素能受体激动剂的舒张反应。Y-27632(0.3 - 30微摩尔)引起了与乙酰甲胆碱(0.3 - 3微摩尔)预收缩的浓度依赖性减弱。用Y-27632(1微摩尔)预处理显著(P<0.05)增强了沙丁胺醇(0.3 - 100纳摩尔)和特布他林(0.3纳摩尔 - 1微摩尔)诱导的舒张。这些结果表明,ROCK抑制剂可能成为一种新型支气管扩张剂,并且其与β2-肾上腺素能受体激动剂的联合可能成为哮喘长期治疗的新策略。